Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.
Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.
These notes describe the products in the RTSM / IRT guide.
Endpoint Clinical RTSM
Best for
Sponsors who want an RTSM specialist with self-service study changes and central pharmacy workflows
What to consider
Endpoint Clinical is an RTSM specialist with two platforms: PULSE, with 20+ self-service modules, and the newer Elosity, which claims 2-6 week study setup and adds direct-to-patient shipping. Its Bluefin product adds supply forecasting. Public pages name few randomization methods, and the only named attestation is SOC 2 Type II.
Oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform
What to consider
Suvoda runs its RTSM on one platform with eCOA, eConsent and Greenphire patient payments, and offers pre-built API integrations with major EDCs. It publishes the shortest build claim on this list (kickoff to UAT in as little as two weeks, footnoted as preliminary testing) and an annual SOC 2 Type 2 audit for RTSM. Its public pages name stratification and adaptive designs but not minimization.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Endpoint Clinical RTSM vs Suvoda RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category feature
Endpoint Clinical RTSM
Suvoda RTSM
Randomization and blindingFeature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Endpoint Clinical RTSM
Supported
Endpoint cites complex protocols, dosing strategies, adaptive designs and patient rollover, but its product pages do not name specific allocation methods.
Adaptive protocol support establishes base support; allocation methods are not named.
Suvoda RTSM
Supported
Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.
Direct-to-patient delivery is stated alongside Bluefin supply forecasting.
Suvoda RTSM
Extended support
The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.
A study-setup timeline and version-tracked changes without interrupting live studies are stated.
Suvoda RTSM
Supported
Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.
The UAT timeline concerns preliminary testing; permissioned changes do not establish uninterrupted live use.
Integrations and platformFeature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Endpoint Clinical RTSM
Extended support
Endpoint describes pre-built, API-based integrations with EDC, eCOA, eConsent and CTMS, but names no specific systems and has no EDC or eCOA of its own.
A SOC attestation establishes base security evidence; product-specific trial controls and public report access are not established.
Suvoda RTSM
Supported
Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.